繁体中文
设为首页
加入收藏
当前位置:药品说明书与价格首页 >> 肿瘤 >> 新药推荐 >> 曲贝替定冻干粉静脉滴注YONDELIS(ET-743 trabectedin)

曲贝替定冻干粉静脉滴注YONDELIS(ET-743 trabectedin)

2015-11-08 04:30:34  作者:新特药房  来源:互联网  浏览次数:213  文字大小:【】【】【
简介: 抗癌药YONDELIS(Trabectedin(ET-743))获美国FDA扩展治疗晚期软组织肉瘤2015年10月23日,美国食品药品监督管理局(以下简称FDA)批准化疗药Yondelis(trabectedin)用于治疗不可切除的或晚期(转移性 ...

新型抗癌药YONDELIS(TRABECTEDIN/POWDER IV (INFUSION)ET-743)获美国FDA扩展治疗晚期软组织肉瘤
2015年10月23日,美国食品药品监督管理局(以下简称FDA)批准化疗药Yondelis(trabectedin)用于治疗不可切除的或晚期(转移性)脂肪肉瘤和平滑肌肉瘤,其适应人群是既往接受过蒽环类化疗药物治疗的患者。
据美国国家癌症研究所的报道,软组织肉瘤是癌细胞形成于人体软组织的疾病,人体软组织包括肌肉、肌腱、脂肪、血管、淋巴管、神经、关节周围组织等。软组织肉瘤几乎可形成于人体的任何部位,但最常见于头部、颈部、四肢、躯干和腹部。
脂肪肉瘤和平滑肌肉瘤是软组织肉瘤的两种具体类型,前者形成于脂肪细胞,后者形成于平滑肌细胞。据估计,2014年美国有12,000名软组织肉瘤新增病例。
“治疗晚期或转移性软组织肉瘤的难题是患者可得到的有效治疗选择少之又少,”FDA药品评价与研究中心的血液与肿瘤药品办公室主任Richard Pazdur博士说。“化疗药Yondelis的获批为晚期或转移性脂肪肉瘤和平滑肌肉瘤患者提供了一种治疗选择。”
一项入组518名受试者的临床试验证实了Yondelis治疗转移性或复发性平滑肌肉瘤或脂肪肉瘤的安全性与有效性。经随机分配,这些受试者中有345人接受Yondelis治疗,其余173人使用另一种化疗药dacarbazine。平均而言,Yondelis治疗组患者的无进展生存期约为4.2个月,相比之下,dacarbazine治疗组患者只有1.5个月的无进展生存期。
Yondelis治疗组患者的最常见副作用有恶心、疲劳、呕吐、腹泻、便秘、食欲减退、呼吸急促(呼吸困难)、头痛、组织肿胀(外周性水肿)、抗感染白细胞减少(中性粒细胞减少症)、血小板计数低(血小板减少症)、红细胞计数低(贫血)、肝酶升高和血中白蛋白含量减少。
Yondelis获批文件中的黑框警告提醒医疗服务提供者Yondelis治疗引起严重及致命性血液感染(中性粒细胞减少症性败血症)、肌肉溶解(横纹肌溶解症)、肝损伤(肝毒性)、静脉或导管周围渗漏、组织坏死和心力衰竭(心肌病)的风险。已知对抗癌药trabectedin过敏的患者不得使用Yondelis。
医疗服务提供者还应告知女性患者Yondelis治疗对发育中的胎儿造成的潜在危险。另外,使用Yondelis的女性患者不得用母乳喂养婴儿。
Yondelis由位于美国新泽西州力登的杨森制药公司推广上市。
---------------------------------------------------
注:以下产品美国包装,采购以咨询为准
---------------------------------------------------
YONDELIS 1MG PWD SDV
YONDELIS 1MG SDV LYO PWD PF 1/EA  TRABECTEDIN  59676-0610-01 

HIGHLIGHTS OF PRESCRIBING INFORMAON
These highlights do not include all the information needed to use YONDELIS ® safely and effectively. See full prescribing information for YONDELIS.
YONDELIS (trabectedin) for injection, for intravenous use
Initial U.S. Approval: 2015
RECENT MAJOR CHANGES

Dosage and Administration (2.1, 2.3) 07/2016
Warnings and Precautions (5.3) 07/2016
INDICATIONS AND USAGE
YONDELIS is an alkylating drug indicated for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen (1)
DOSAGE AND ADMINISTRATION
Administer at 1.5 mg/m2 body surface area as a 24-hour intravenous infusion, every 3 weeks through a central venous line (2.1, 2.5)
Premedication: dexamethasone 20 mg IV, 30 min before each infusion (2.2)
Hepatic Impairment: Administer at 0.9 mg/m2 body surface area as a 24-hour intravenous infusion, every 3 weeks through a central venous line in patients with moderate hepatic impairment (2.1, 5.3, 8.6, 12.3)
DOSAGE FORMS AND STRENGTHS
For injection: 1 mg sterile lyophilized powder in a single-dose vial (3)
CONTRAINDICATIONS
Known hypersensitivity to trabectedin (4)
WARNINGS AND PRECAUTIONS
Neutropenic sepsis: Severe, and fatal, neutropenic sepsis may occur. Monitor neutrophil count during treatment. Withhold YONDELIS for Grade 2 or greater neutropenia (5.1)
Rhabdomyolysis: Rhabdomyolysis may occur; withhold YONDELIS for severe or life-threatening increases in creatine phosphokinase level (5.2)
Hepatotoxicity: Hepatotoxicity may occur. Monitor and delay and/or reduce dose if needed (5.3)
Cardiomyopathy: Severe and fatal cardiomyopathy can occur. Withhold YONDELIS in patients with left ventricular dysfunction (5.4)
Embryofetal toxicity: Can cause fetal harm. Advise of potential risk to a fetus and use effective contraception (5.6, 8.1, 8.3)
ADVERSE REACTIONS
The most common (≥20%) adverse reactions are nausea, fatigue, vomiting, constipation, decreased appetite, diarrhea, peripheral edema, dyspnea, and headache. The most common (≥5%) grades 3–4 laboratory abnormalities are: neutropenia, increased ALT, thrombocytopenia, anemia, increased AST, and increased creatine phosphokinase. (6.1)
To report SUSPECTED ADVERSE REACTIONS, contact Janssen Biotech, Inc. at 1-800-526-7736 (1-800-JANSSEN) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
DRUG INTERACTIONS
CYP3A inhibitors: Avoid concomitant strong CYP3A inhibitors (7.1)
CYP3A inducers: Avoid concomitant strong CYP3A inducers (7.2)
USE IN SPECIFIC POPULATIONS
Lactation: Breastfeeding not recommended (8.2)
Do not administer YONDELIS to patients with severe hepatic impairment (5.3, 8.6, 12.3)
See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.
Revised: 7/2016
FULL PRESCRIBING INFORMATION: CONTENTS*
1 INDICATIONS AND USAGE
YONDELIS® is indicated for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen [see Clinical Studies (14)].
2 DOSAGE AND ADMINISTRATION
2.1 Recommended Dose and Schedule
The recommended dose is 1.5 mg/m2 administered as an intravenous infusion over 24 hours through a central venous line every 21 days (3 weeks), until disease progression or unacceptable toxicity, in patients with normal bilirubin and AST or ALT less than or equal to 2.5 times the upper limit of normal.
Hepatic Impairment: The recommended dose is 0.9 mg/m2 in patients with moderate hepatic impairment (bilirubin levels 1.5 times to 3 times the upper limit of normal, and AST and ALT less than 8 times the upper limit of normal). Do not administer YONDELIS to patients with severe hepatic impairment (bilirubin levels above 3 times to 10 times the upper limit of normal, and any AST and ALT) [see Warnings and Precautions (5.3), Use in Specific Populations (8.6), and Clinical Pharmacology (12.3)].
2.2 Premedication
Administer dexamethasone 20 mg intravenously 30 minutes prior to each dose of YONDELIS.
2.3 Dose Modifications
Permanently discontinue YONDELIS for:
Persistent adverse reactions requiring a delay in dosing of more than 3 weeks.
Adverse reactions requiring dose reduction following YONDELIS administered at 1.0 mg/m2 for patients with normal hepatic function or at 0.3 mg/m2 for patients with pre-existing moderate hepatic impairment.
Severe liver dysfunction all of the following: bilirubin two times the upper limit of normal and AST or ALT three times the upper limit of normal with alkaline phosphatase less than two times the upper limit of normal in the prior treatment cycle for patients with normal liver function at baseline.
Exacerbation of liver dysfunction in patients with pre-existing moderate hepatic impairment.
The recommended dose modifications for adverse reactions are listed in Table 1. Once reduced, the dose of YONDELIS should not be increased in subsequent treatment cycles.
Table 1: Recommended Dose Modification

Laboratory Result or Adverse Reaction DELAY next dose of YONDELIS for up to 3 weeks REDUCE next dose of YONDELIS by one dose level for adverse reaction(s) during prior cycle
Platelets Less than 100,000 platelets/microliter Less than 25,000 platelets/microliter
Absolute neutrophil count Less than 1,500 neutrophils/microliter
  • Less than 1,000 neutrophils/microliter with fever/infection
  • Less than 500 neutrophils/microliter lasting more than 5 days
Total bilirubin* Greater than the upper limit of normal Greater than the upper limit of normal
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT)* More than 2.5 times the upper limit of normal More than 5 times the upper limit of normal
Alkaline phosphatase (ALP)* More than 2.5 times the upper limit of normal More than 2.5 times the upper limit of normal
Creatine phosphokinase More than 2.5 times the upper limit of normal More than 5 times the upper limit of normal
Decreased left ventricular ejection fraction
  • Less than lower limit of normal; or
  • Clinical evidence of cardiomyopathy
  • Absolute decrease of 10% or more from baseline and less than lower limit of normal; or
  • Clinical evidence of cardiomyopathy
Other non-hematologic adverse reactions Grade 3 or 4 Grade 3 or 4
Permanently discontinue YONDELIS when liver dysfunction is exacerbated for patients with pre-existing moderate hepatic impairment.
The recommended starting doses and dose reductions for YONDELIS are listed in Table 2:
Table 2: Recommended Starting Doses and Dose Reductions

Starting Dose and Dose Reduction For patients with normal hepatic function or mild hepatic impairment prior to initiation of YONDELIS treatment For patients with moderate hepatic impairment prior to initiation of YONDELIS treatment
Starting Dose 1.5 mg/m2 0.9 mg/m2
Dose Reduction
  First dose reduction 1.2 mg/m2 0.6 mg/m2
  Second dose reduction 1.0 mg/m2 0.3 mg/m2
Including patients with bilirubin 1 to 1.5 times the upper limit of normal, and any AST or ALT.
2.4 Preparation for Administration
YONDELIS is a cytotoxic drug. Follow applicable special handling and disposal procedures.1
Using aseptic technique, inject 20 mL of Sterile Water for Injection, USP into the vial. Shake the vial until complete dissolution. The reconstituted solution is clear, colorless to pale brownish-yellow, and contains 0.05 mg/mL of trabectedin.
Inspect for particulate matter and discoloration prior to further dilution. Discard vial if particles or discoloration are observed.
Immediately following reconstitution, withdraw the calculated volume of trabectedin and further dilute in 500 mL of 0.9% Sodium Chloride, USP or 5% Dextrose Injection, USP.
Do not mix YONDELIS with other drugs.
Discard any remaining solution within 30 hours of reconstituting the lyophilized powder.
YONDELIS diluted solution is compatible with Type I colorless glass vials, polyvinylchloride (PVC) and polyethylene (PE) bags and tubing, PE and polypropylene (PP) mixture bags, polyethersulfone (PES) in-line filters, titanium, platinum or plastic ports, silicone and polyurethane catheters, and pumps having contact surfaces made of PVC, PE, or PE/PP.
2.5 Administration
Infuse the reconstituted, diluted solution over 24 hours through a central venous line using an infusion set with a 0.2 micron polyethersulfone (PES) in-line filter to reduce the risk of exposure to adventitious pathogens that may be introduced during solution preparation.
Complete infusion within 30 hours of initial reconstitution. Discard any unused portion of the reconstituted product or of the infusion solution.
3 DOSAGE FORMS AND STRENGTHS
For injection: 1 mg, lyophilized powder in single-dose vial for reconstitution.
4 CONTRAINDICATIONS
YONDELIS is contraindicated in patients with known severe hypersensitivity, including anaphylaxis, to trabectedin.
5 WARNINGS AND PRECAUTIONS
5.1 Neutropenic Sepsis
Neutropenic sepsis, including fatal cases, can occur with YONDELIS. In Trial 1, the incidence of Grade 3 or 4 neutropenia, based on laboratory values, in patients receiving YONDELIS was 43% (161/378). The median time to the first occurrence of Grade 3 or 4 neutropenia was 16 days (range: 8 days to 9.7 months); the median time to complete resolution of neutropenia was 13 days (range: 3 days to 2.3 months). Febrile neutropenia (fever ≥38.5°C with Grade 3 or 4 neutropenia) occurred in 18 patients (5%) treated with YONDELIS. Ten patients (2.6%) experienced neutropenic sepsis, 5 of whom had febrile neutropenia, which was fatal in 4 patients (1.1%).
Assess neutrophil count prior to administration of each dose of YONDELIS and periodically throughout the treatment cycle. Withhold YONDELIS for neutrophil counts of less than 1,500 cells/microliter on the day of dosing. Permanently reduce the dose of YONDELIS for life-threatening or prolonged, severe neutropenia in the preceding cycle [see Dosage and Administration (2.3)].
5.2 Rhabdomyolysis
YONDELIS can cause rhabdomyolysis and musculoskeletal toxicity. In Trial 1, rhabdomyolysis leading to death occurred in 3 (0.8%) of the 378 patients receiving YONDELIS. Elevations in creatine phosphokinase (CPK) occurred in 122 (32%) of the 378 patients receiving YONDELIS, including Grade 3 or 4 CPK elevation in 24 patients (6%), compared to 15 (9%) of the 172 patients receiving dacarbazine with any CPK elevation, including 1 patient (0.6%) with Grade 3 CPK elevation. Among the 24 patients receiving YONDELIS with Grade 3 or 4 CPK elevation, renal failure occurred in 11 patients (2.9%); rhabdomyolysis with the complication of renal failure occurred in 4 of these 11 patients (1.1%). The median time to first occurrence of Grade 3 or 4 CPK elevations was 2 months (range: 1 to 11.5 months). The median time to complete resolution was 14 days (range: 5 days to 1 month).
Assess CPK levels prior to each administration of YONDELIS. Withhold YONDELIS for serum CPK levels more than 2.5 times the upper limit of normal. Permanently discontinue YONDELIS for rhabdomyolysis [see Dosage and Administration (2.3)].
5.3 Hepatotoxicity
Hepatotoxicity, including hepatic failure, can occur with YONDELIS. Patients with serum bilirubin levels above the upper limit of normal or AST or ALT levels >2.5 × upper limit of normal were not enrolled in Trial 1. In Trial 1, the incidence of Grade 3–4 elevated liver function tests (LFTs; defined as elevations in ALT, AST, total bilirubin, or alkaline phosphatase) was 35% (134/378) in patients receiving YONDELIS. The median time to development of Grade 3–4 elevation in ALT or AST was 29 days (range: 3 days to 11.5 months). Of the 134 patients with Grade 3–4 elevations in LFTs, 114 (85%) experienced complete resolution with the median time to complete resolution of 13 days (range: 4 days to 4.4 months).
In Trial 1, the incidence of drug-induced liver injury (defined as concurrent elevation in ALT or AST of more than three times the upper limit of normal, alkaline phosphatase less than two times the upper limit of normal, and total bilirubin at least two times the upper limit of normal) was 1.3% (5/378) in patients receiving YONDELIS. ALT or AST elevation greater than eight times the upper limit of normal occurred in 18% (67/378) of patients receiving YONDELIS.
Assess LFTs prior to each administration of YONDELIS and as clinically indicated based on underlying severity of pre-existing hepatic impairment. Manage elevated LFTs with treatment interruption, dose reduction, or permanent discontinuation based on severity and duration of LFT abnormality [see Dosage and Administration (2.3) and Use in Specific Populations (8.6)].
5.4 Cardiomyopathy
Cardiomyopathy including cardiac failure, congestive heart failure, ejection fraction decreased, diastolic dysfunction, or right ventricular dysfunction can occur with YONDELIS. In Trial 1, patients with a history of New York Heart Association Class II to IV heart failure or abnormal left ventricular ejection fraction (LVEF) at baseline were ineligible. In Trial 1, cardiomyopathy occurred in 23 patients (6%) receiving YONDELIS and in four patients (2.3%) receiving dacarbazine. Grade 3 or 4 cardiomyopathy occurred in 15 patients (4%) receiving YONDELIS and 2 patients (1.2%) receiving dacarbazine; cardiomyopathy leading to death occurred in 1 patient (0.3%) receiving YONDELIS and in none of the patients receiving dacarbazine. The median time to development of Grade 3 or 4 cardiomyopathy in patients receiving YONDELIS was 5.3 months (range: 26 days to 15.3 months).
Assess LVEF by echocardiogram or multigated acquisition (MUGA) scan before initiation of YONDELIS and at 2- to 3-month intervals thereafter until YONDELIS is discontinued. Withhold YONDELIS for LVEF below lower limit of normal. Permanently discontinue YONDELIS for symptomatic cardiomyopathy or persistent left ventricular dysfunction that does not recover to lower limit of normal within 3 weeks [see Dosage and Administration (2.3)].
5.5 Extravasation Resulting in Tissue Necrosis
Extravasation of YONDELIS, resulting in tissue necrosis requiring debridement, can occur. Evidence of tissue necrosis can occur more than 1 week after the extravasation. There is no specific antidote for extravasation of YONDELIS. Administer YONDELIS through a central venous line [see Dosage and Administration (2.5)].
5.6 Embryofetal Toxicity
Based on its mechanism of action, YONDELIS can cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential to use effective contraception during therapy and for at least 2 months after the last dose of YONDELIS. Advise males with female partners of reproductive potential to use effective contraception during therapy and for at least 5 months after the last dose of YONDELIS [see Use in Specific Populations (8.1, 8.3)].
6 ADVERSE REACTIONS
The following adverse reactions are discussed in more detail in other sections of the labeling:
Anaphylaxis [see Contraindications (4)]
Neutropenic Sepsis [see Warnings and Precautions (5.1)]
Rhabdomyolysis [see Warnings and Precautions (5.2)]
Hepatotoxicity [see Warnings and Precautions (5.3)]
Cardiomyopathy [see Warnings and Precautions (5.4)]
Extravasation Resulting in Tissue Necrosis [see Warnings and Precautions (5.5)]
6.1 Adverse Reactions in Clinical Trials
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The data described below reflect exposure to YONDELIS in 755 patients with soft tissue sarcoma including 197 (26%) patients exposed to YONDELIS for greater than or equal to 6 months and 57 (8%) patients exposed to YONDELIS for greater than or equal to 1 year. The safety of YONDELIS was evaluated in six open-label, single-arm trials, in which 377 patients received YONDELIS and one open-label, randomized, active-controlled clinical trial in which 378 patients received YONDELIS (Trial 1). All patients received YONDELIS at the recommended dosing regimen of 1.5 mg/m2 administered as an intravenous infusion over 24 hours once every 3 weeks (q3wk, 24-h). The median age was 54 years (range: 18 to 81 years), 63% were female, and all patients had metastatic soft tissue sarcoma.
Tables 3 and 4 present selected adverse reactions and laboratory abnormalities, respectively, observed in Trial 1, an open-label, randomized (2:1), active-controlled trial in which 550 patients with previously treated leiomyosarcoma or liposarcoma (dedifferentiated, myxoid round cell, or pleomorphic) received YONDELIS 1.5 mg/m2 intravenous infusion over 24 hours once every 3 weeks (n=378) or dacarbazine 1000 mg/m2 intravenous infusion over 20 to 120 minutes once every 3 weeks (n=172) [see Clinical Studies (14)]. All patients treated with YONDELIS were required to receive dexamethasone 20 mg intravenous injection 30 minutes prior to start of the YONDELIS infusion.
In Trial 1, patients had been previously treated with an anthracycline- and ifosfamide-containing regimen or with an anthracycline-containing regimen and one additional cytotoxic chemotherapy regimen. The trial excluded patients with known central nervous system metastasis, elevated serum bilirubin or significant chronic liver disease, such as cirrhosis or active hepatitis, and history of myocardial infarction within 6 months, history of New York Heart Association Class II to IV heart failure, or abnormal left ventricular ejection fraction at baseline. The median age of patients in Trial 1 was 57 years (range: 17 to 81 years), with 69% female, 77% White, 12% Black or African American, 4% Asian, and <1% American Indian or Alaska Native. The median duration of exposure to trabectedin was 13 weeks (range: 1 to 127 weeks) with 30% of patients exposed to YONDELIS for greater than 6 months and 7% of patients exposed to YONDELIS for greater than 1 year.
In Trial 1, adverse reactions resulting in permanent discontinuation of YONDELIS occurred in 26% (98/378) of patients; the most common were increased liver tests (defined as ALT, AST, alkaline phosphatase, bilirubin) (5.6%), thrombocytopenia (3.4%), fatigue (1.6%), increased creatine phosphokinase (1.1%), and decreased ejection fraction (1.1%). Adverse reactions that led to dose reductions occurred in 42% (158/378) of patients treated with YONDELIS; the most common were increased liver tests (24%), neutropenia (including febrile neutropenia) (8%), thrombocytopenia (4.2%), fatigue (3.7%), increased creatine phosphokinase (2.4%), nausea (1.1%), and vomiting (1.1%). Adverse reactions led to dose interruptions in 52% (198/378) of patients treated with YONDELIS; the most common were neutropenia (31%), thrombocytopenia (15%), increased liver tests (6%), fatigue (2.9%), anemia (2.6%), increased creatinine (1.1%), and nausea (1.1%).
The most common adverse reactions (≥20%) were nausea, fatigue, vomiting, constipation, decreased appetite, diarrhea, peripheral edema, dyspnea, and headache. The most common laboratory abnormalities (≥20%) were increases in AST or ALT, increased alkaline phosphatase, hypoalbuminemia, increased creatinine, increased creatine phosphokinase, anemia, neutropenia, and thrombocytopenia.
Table 3: Selected Adverse Reactions* Occurring in ≥10% of Patients Receiving YONDELIS and at a Higher Incidence than in the Control Arm - Trial 1 

YONDELIS
(N=378)
Dacarbazine
(N=172)
System Organ Class
  Adverse Reaction
All Grades†
(%)
Grades 3–4
(%)
All Grades
(%)
Grades 3–4
(%)
Gastrointestinal disorders
    Nausea 75 7 50 1.7
    Vomiting 46 6 22 1.2
    Constipation 37 0.8 31 0.6
    Diarrhea 35 1.6 23 0
General disorders and administration site conditions
    Fatigue‡ 69 8 52 1.7
    Peripheral edema 28 0.8 13 0.6
Metabolism and nutrition disorders
    Decreased appetite 37 1.9 21 0.6
Respiratory, thoracic and mediastinal disorders
    Dyspnea 25 4.2 20 1.2
Nervous system disorders
    Headache 25 0.3 19 0
Musculoskeletal and connective tissue disorders
    Arthralgia 15 0 8 1.2
    Myalgia 12 0 6 0
Psychiatric disorders
    Insomnia 15 0.3 9 0
Limited to adverse reactions at a rate of ≥10% in the trabectedin arm and at a rate higher in the trabectedin arm compared with dacarbazine arm by ≥5% in overall incidence or by ≥2% for Grade 3–4 adverse reactions.
Toxicity grade is based on NCI common toxicity criteria, version 4.0.
Fatigue is a composite of the following adverse event terms: fatigue, asthenia, and malaise.
Other clinically important adverse reactions observed in <10% of patients (N=755) with soft tissue sarcoma receiving YONDELIS were:
Nervous system disorders: peripheral neuropathy, paresthesia, hypoesthesia.
Respiratory, thoracic, and mediastinal disorders: pulmonary embolism.
Table 4: Incidence of Selected Treatment-Emergent Laboratory Abnormalities* - Trial 1 

Laboratory Abnormalities YONDELIS Dacarbazine
All Grades
(%)
Grades 3–4
(%)
All Grades
(%)
Grades 3–4
(%)
YONDELIS group (range: 373 to 377 patients) and dacarbazine group (range: 166 to 168 patients).
  Chemistry
    Increased ALT 90 31 33 0.6
    Increased AST 84 17 32 1.2
    Increased alkaline phosphatase 70 1.6 60 0.6
    Hypoalbuminemia 63 3.7 51 3.0
    Increased creatinine 46 4.2 29 1.2
    Increased creatine phosphokinase 33 6.4 9 0.6
    Hyperbilirubinemia 13 1.9 5 0.6
  Hematology
    Anemia 96 19 79 12
    Neutropenia 66 43 47 26
    Thrombocytopenia 59 21 57 20
Treatment-emergent laboratory abnormalities including those higher in the trabectedin arm compared with the dacarbazine arm by ≥5% (all Grades) or by ≥2% (Grade 3–4). Incidence based on number of patients who had both baseline and at least one on-study laboratory measurement. 
7 DRUG INTERACTIONS
7.1 Effect of Cytochrome CYP3A Inhibitors
Coadministration of YONDELIS with ketoconazole, a strong CYP3A inhibitor, increased systemic exposure of trabectedin by 66%. Avoid using strong CYP3A inhibitors (e.g., oral ketoconazole, itraconazole, posaconazole, voriconazole, clarithromycin, telithromycin, indinavir, lopinavir, ritonavir, boceprevir, nelfinavir, saquinavir, telaprevir, nefazodone, conivaptan) in patients taking YONDELIS. Avoid taking grapefruit or grapefruit juice during YONDELIS treatment. If a strong CYP3A inhibitor for short-term use (i.e., less than 14 days) must be used, administer the strong CYP3A inhibitor 1 week after the YONDELIS infusion, and discontinue it the day prior to the next YONDELIS infusion [see Clinical Pharmacology (12.3)].
7.2 Effect of Cytochrome CYP3A Inducers
Coadministration of YONDELIS with rifampin, a strong CYP3A inducer, decreased systemic exposure of trabectedin by 31%. Avoid using strong CYP3A inducers (e.g., rifampin, phenobarbital, St. John's wort) in patients taking YONDELIS [see Clinical Pharmacology (12.3)].
8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
Risk Summary
Based on its mechanism of action, trabectedin can cause fetal harm when administered during pregnancy [see Clinical Pharmacology (12.1)]. There are no available data with the use of YONDELIS during pregnancy. Animal reproductive and developmental studies at relevant doses have not been conducted with trabectedin; however, placental transfer of trabectedin was demonstrated in pregnant rats. Advise pregnant woman of the potential risk to a fetus. The background risk of major birth defects and miscarriage for the indicated population are unknown; however, the background risk in the U.S. general population of major birth defects is 2 to 4% and of miscarriage is 15 to 20% of clinically recognized pregnancies.
8.2 Lactation
Risk Summary
There are no data on the presence of trabectedin in human milk, the effects on the breastfed infant, or the effects on milk production. Because of the potential for serious adverse reactions from YONDELIS in breastfed infants, advise a nursing woman to discontinue nursing during treatment with YONDELIS.
8.3 Females and Males of Reproductive Potential
Contraception
Females
Advise female patients of reproductive potential to use effective contraception during and for 2 months after the last dose of YONDELIS [see Use in Specific Populations (8.1)].
Males
YONDELIS may damage spermatozoa, resulting in possible genetic and fetal abnormalities. Advise males with a female sexual partner of reproductive potential to use effective contraception during and for 5 months after the last dose of YONDELIS [see Nonclinical Toxicology (13.1)].
Infertility
YONDELIS may result in decreased fertility in males and females [see Nonclinical Toxicology (13.1)].
8.4 Pediatric Use
Safety and effectiveness in pediatric patients have not been established.
8.5 Geriatric Use
Clinical studies of YONDELIS did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.
8.6 Hepatic Impairment
The mean trabectedin exposure was (97%) higher in patients with moderate (bilirubin levels 1.5 to 3.0 times the upper limit of normal, and AST and ALT less than 8 times the upper limit of normal) hepatic impairment compared to patients with normal (total bilirubin ≤ the upper limit of normal, and AST and ALT ≤ the upper limit of normal) liver function. Reduce YONDELIS dose in patients with moderate hepatic impairment [see Dosage and Administration (2.1) and Clinical Pharmacology (12.3)].
Do not administer YONDELIS to patients with severe hepatic impairment (bilirubin levels above 3 times to 10 times the upper limit of normal, and any AST and ALT) [see Warnings and Precautions (5.3)].
8.7 Renal Impairment
No dose adjustment is recommended in patients with mild [creatinine clearance (CLcr) 60–89 mL/min] or moderate (CLcr of 30–59 mL/min) renal impairment.
The pharmacokinetics of trabectedin has not been evaluated in patients with severe renal impairment (CLcr <30 mL/min) or end stage renal disease [see Clinical Pharmacology (12.3)].
10 OVERDOSAGE
There is no specific antidote for YONDELIS. Hemodialysis is not expected to enhance the elimination of YONDELIS because trabectedin is highly bound to plasma proteins (97%) and not significantly renally excreted.
11 DESCRIPTION
Trabectedin is an alkylating agent with the chemical name (1'R,6R,6aR,7R,13S,14S,16R)-5-(acetyloxy)-3',4',6,6a,7,13,14,16-octahydro-6',8,14-trihydroxy-7',9-dimethoxy-4,10,23-trimethyl-spiro[6,16-(epithiopropanoxymethano)-7,13-imino-12H-1,3-dioxolo[7,8]isoquino[3,2-b][3]benzazocine-20,1'(2'H)-isoquinolin]-19-one. The molecular formula is C39H43N3O11S. The molecular weight is 761.84 daltons. The chemical structure is shown below:

Trabectedin is hydrophobic and has a low solubility in water.
YONDELIS (trabectedin) for injection is supplied as a sterile lyophilized white to off-white powder/cake in a single-dose vial. Each single-dose vial contains 1 mg of trabectedin, 27.2 mg potassium dihydrogen phosphate, 400 mg sucrose, and phosphoric acid and potassium hydroxide (for pH adjustment to 3.6 – 4.2).
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
Trabectedin is an alkylating drug that binds guanine residues in the minor groove of DNA, forming adducts and resulting in a bending of the DNA helix towards the major groove. Adduct formation triggers a cascade of events that can affect the subsequent activity of DNA binding proteins, including some transcription factors, and DNA repair pathways, resulting in perturbation of the cell cycle and eventual cell death.
12.2 Pharmacodynamics
Cardiac Electrophysiology
The effect of trabectedin on the QT/QTc interval was evaluated in 75 patients who received placebo on day 1 and trabectedin (1.3 mg/m2) as a 3-hour intravenous infusion on day 2. No patients in the study showed a QTc interval exceeding 500 msec or more than 60 msec increase from baseline, and no large changes in the mean QTc interval (i.e., >20 msec) were observed.
12.3 Pharmacokinetics
The pharmacokinetics of trabectedin is characterized by a rapid decline phase at the end of the infusion and slower exponential phases. Population pharmacokinetic analyses suggest that the pharmacokinetics of trabectedin is dose-proportional (over the dose range of 0.024 to 1.8 mg/m2) and exposure is time-independent. No accumulation of trabectedin in plasma is observed upon repeated administrations every 3 weeks.
Distribution
Binding of trabectedin to human plasma proteins was approximately 97%, independent of trabectedin concentrations ranging from 10 ng/mL to 100 ng/mL. Steady state volume of distribution of trabectedin exceeds 5000 L.
Elimination
The estimated mean (% coefficient of variation) clearance of trabectedin is 31.5 L/hr (50%) and the terminal elimination half-life is approximately 175 hours.
Metabolism
CYP3A is the predominant CYP enzyme responsible for the hepatic metabolism of trabectedin.
Trabectedin was extensively metabolized with negligible unchanged drug in urine and feces following administration of trabectedin to humans.
Excretion
In patients with solid tumors, following a 3-hour or a 24-hour intravenous infusion of 14C-labeled trabectedin, 64% of the total administered radioactive dose was recovered in 24 days, with 58% in feces and 6% in urine.
Specific Populations
The following population characteristics are not associated with a clinically significant effect on the pharmacokinetics of trabectedin: sex, age (19 to 83 years), body weight (36 to 148 kg), body surface area (0.9 to 2.8 m2), mild hepatic impairment, or mild to moderate renal impairment. The effects of severe hepatic impairment, severe renal impairment or end stage renal disease on trabectedin exposure are unknown.
Hepatic Impairment
The geometric mean dose normalized trabectedin exposure (AUC) increased by 97% (90% CI: 20%, 222%) in patients with moderate hepatic impairment following administration of a single YONDELIS dose of 0.58 mg/m2 or 0.9 mg/m2 compared to patients with normal liver function following administration of a single YONDELIS dose of 1.3 mg/m2 [see Dosage and Administration (2.1) and Use in Specific Populations (8.6)].
Drug Interactions
Effect of Strong CYP3A Inhibitors on Trabectedin
Coadministration of multiple doses of ketoconazole (200 mg twice daily for 7.5 days) with a single dose of YONDELIS (0.58 mg/m2) on day 1 increased trabectedin dose-normalized AUC by 66% and Cmax by 22% compared to a single YONDELIS dose (1.3 mg/m2) given alone.
Effect of Strong CYP3A Inducers on Trabectedin
Coadministration of multiple doses of rifampin (600 mg daily for 6 days) with a single YONDELIS dose (1.3 mg/m2) on day 6 decreased trabectedin AUC by 31% and Cmax by 21% compared to a single YONDELIS dose (1.3 mg/m2) given alone.
Effect of Trabectedin on CYP Enzymes
In vitro, trabectedin has limited inhibition or induction potential of major CYP enzymes (CYP1A2, 2A6, 2B6, 2C9, 2C19, 2D6, 2E1, and 3A4).
13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
Trabectedin is genotoxic in both in vitro and in vivo studies. Long-term carcinogenicity studies have not been performed.
Fertility studies with trabectedin were not performed. In male rats there were limited histopathological signs of hemorrhage and degeneration in the testes following repeated administration of trabectedin at doses approximately 0.2 times the 1.5 mg/m2 human dose based on body surface area.
14 CLINICAL STUDIES
The clinical efficacy and safety of YONDELIS in patients with metastatic or recurrent leiomyosarcoma or liposarcoma were demonstrated in Trial 1, a randomized (2:1), open-label, active-controlled trial comparing treatment with YONDELIS 1.5 mg/m2 as a 24-hour continuous intravenous infusion once every 3 weeks to dacarbazine 1000 mg/m2 intravenous infusion (20 to 120 minutes) once every 3 weeks. Treatment continued in both arms until disease progression or unacceptable toxicity; all patients in the YONDELIS arm were required to receive dexamethasone 20 mg intravenous injection prior to each YONDELIS infusion. Patients were required to have unresectable, locally advanced or metastatic leiomyosarcoma or liposarcoma (dedifferentiated, myxoid round cell, or pleomorphic) and previous treatment with an anthracycline- and ifosfamide-containing regimen or an anthracycline-containing regimen and one additional cytotoxic chemotherapy regimen. Randomization was stratified by subtype of soft tissue sarcoma (leiomyosarcoma vs. liposarcoma), ECOG performance status (0 vs. 1), and number of prior chemotherapy regimens (1 vs. ≥2). The efficacy outcome measures were investigator-assessed progression-free survival (PFS) according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1), overall survival (OS), objective response rate (ORR), and duration of response (DOR). Patients in the dacarbazine arm were not offered YONDELIS at the time of disease progression.
A total of 518 patients were randomized, 345 to the YONDELIS arm and 173 patients to the dacarbazine arm. The median patient age was 56 years (range: 17 to 81); 30% were male; 76% White, 12% Black, and 4% Asian; 73% had leiomyosarcomas and 27% liposarcomas; 49% had an ECOG PS of 0; and 89% received ≥2 prior chemotherapy regimens. The most common (≥20%) pre-study chemotherapeutic agents administered were doxorubicin (90%), gemcitabine (81%), docetaxel (74%), and ifosfamide (59%). Approximately 10% of patients had received pazopanib.
Trial 1 demonstrated a statistically significant improvement in PFS. An exploratory analysis of independent radiology committee-determined PFS, in a subgroup consisting of approximately 60% of the total population, provided similar results to the investigator-determined PFS. Efficacy results from Trial 1 are presented in the table below.
Table 5: Efficacy Results for Trial 1

Efficacy Endpoint YONDELIS
N=345
Dacarbazine
N=173
CR=Complete Response; PR=Partial Response; CI=Confidence Interval, HR=hazard ratio, NE=not estimable.
Progression-free survival
  PFS Events, n (%) 217 (63%) 112 (65%)
    Disease progression 204 109
    Death 13 3
  Median (95% CI) (months) 4.2 (3.0, 4.8) 1.5 (1.5, 2.6)
  HR (95% CI) 0.55 (0.44, 0.70)
 p-value <0.001
Overall survival
  Events, n (%) 258 (67%) 123 (64%)
  Median (95% CI) (months) 13.7 (12.2, 16.0) 13.1 (9.1, 16.2)
  HR (95% CI) 0.93 (0.75, 1.15)
  p-value 0.49
Objective Response Rate (ORR: CR+PR)
  Number of patients (%) 23 (7%) 10 (6%)
  95% CI (4.3, 9.8) (2.8, 10.4)
Duration of Response (CR+ PR)
  Median (95% CI) (months) 6.9 (4.5, 7.6) 4.2 (2.9, NE)
Cox proportional hazards model with treatment group as the only covariate.
Unstratified log rank test.
Based on 384 patients randomized to YONDELIS arm and 193 patients randomized to dacarbazine.
Fisher's exact CI. 
Figure 1: Kaplan-Meier Curves of Progression-Free Survival in Trial 1

15 REFERENCES
1.Hazardous Drugs", OSHA, http://www.osha.gov/SLTC/hazardousdrugs/index.html
16 HOW SUPPLIED/STORAGE AND HANDLING
16.1 How Supplied
YONDELIS is supplied in a glass vial containing 1 mg trabectedin. Each carton contains one vial (NDC: 59676-610-01).
16.2 Storage and Handling
Store YONDELIS vials in a refrigerator at 2ºC to 8ºC (36ºF to 46ºF).
YONDELIS is a cytotoxic drug. Follow applicable special handling and disposal procedures.1
17 PATIENT COUNSELING INFORMATION
Advise the patient to read the FDA-approved patient labeling (Patient Information).
Myelosuppression: Inform patients of the risks of myelosuppression. Instruct patients to immediately contact their healthcare provider for fever or unusual bruising, bleeding, tiredness, or paleness.
Rhabdomyolysis: Advise patients to contact their healthcare provider if they experience severe muscle pain or weakness.
Hepatotoxicity: Advise patients to contact their healthcare provider immediately for yellowing of skin and eyes (jaundice), pain in the upper right quadrant, severe nausea or vomiting, difficulty in concentrating, disorientation, or confusion.
Cardiomyopathy: Advise patients to contact their healthcare provider for new onset chest pain, shortness of breath, fatigue, lower extremity edema, or heart palpitations.
Hypersensitivity: Advise patients to seek immediate medical attention for symptoms of allergic reactions including difficulty breathing, chest tightness, wheezing, severe dizziness or light-headedness, swelling of the lips or skin rash.
Extravasation: Inform patients of the risks of extravasation and to notify their healthcare provider for redness, swelling, itchiness and discomfort or leakage at the injection site.
Embryofetal toxicity: Advise pregnant women of the potential risk to a fetus. Advise females to contact their healthcare provider if they become pregnant, or if pregnancy is suspected, during treatment with YONDELIS [see Warnings and Precautions (5.6) and Use in Specific Populations (8.1)].
Females and males of reproductive potential: Advise females of reproductive potential to use effective contraception during treatment with YONDELIS and for at least 2 months after last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with YONDELIS and for at least 5 months after the last dose [see Warnings and Precautions (5.6) and Use in Specific Populations (8.3)].
Lactation: Advise females not to breastfeed during treatment with YONDELIS [see Use in Specific Populations (8.2)].
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=472bd78e-be17-4b9d-90f4-9482c3aec9ff
抗癌药YONDELIS®(trabectedin(曲贝替定)) 获批的复杂历程
2003年,西班牙生物技术公司PharmaMar公司开发药物物Yondelis(trabectedin,曲贝替定),用于治疗转移性或晚期软组织肉瘤,其报批申请被欧盟人用医药产品委员会(CHMP)的前身CPMP断然拒绝,理由为其若干关键性临床试验的方法学存在问题。
PharmaMar在发现和研制取自海洋的抗癌药方面全球领先,它拥有丰富的药物产品和强大的研发实力。其总部设在马德里,是Zeltia S.A.旗下子公司。
Pharmamar公司当时曾就此问题提起上诉,但未果,因此不得不基于本品的一项STS-201Ⅱ期临床试验数据再次申报,加上公司后来公布的另外补充的3项l临床研究数据,加强了本品疗效的说服力。
2007年9月,该药在欧洲获得治疗晚期软组织肉瘤的许可。Yondelis®是一种全新的、多模块合成的抗癌药,最初从海鞘身上制得。该药物通过不同的药物作用机制阻止肿瘤发展,包括捆绑DNA(脱氧核糖核酸)阻止细胞再生、抑制活化转移和蛋白质参与DNA修复、改变肿瘤微环境。
2009年9月,Yondelis®获得了欧洲药品局对医药产品委员会人类卵巢癌使用的积极推荐,该药当前与强生的聚乙二醇脂质体Doxil(阿霉素)组合用于治疗卵巢癌,2009年11月2日Yondelis®和Doxil以联合疗法治疗卵巢癌获欧洲监管机构批准上市,这一新的适应症的获批也是众望所归。
该组合药已被批准在包括挪威、冰岛以及列支敦士登在内的27个欧盟国家上市。但是其首批投放的国家有英国、澳大利亚、德国、丹麦、瑞士、芬兰以及挪威等。现Yondelis®在77国家中均有销售,是一种用于治疗晚期软组织肉瘤的单一药物;在70个国家中它与Doxil一起治疗复发的铂敏感卵巢癌。
与欧洲大相径庭的是,2009年9月美国FDA因为安全问题过大和疗效并不显着等原因拒绝了Yondelis和Doxil联合疗法的上市申请,其中包括该公司正在进行的关键试验,以及进一步临床药理学研究的总体生存率数据。两年后因为同样原因,公司被迫暂停了这一项目并将其转向恶性肉瘤的研发。
2014年11月24日,PharmaMar在美国研发Yondelis®的战略合作伙伴 Janssen Research & Development(杨森研发有限公司)提交了新药上市申请。2015年2月4日PharmaMar 对外宣布美国 FDA同意优先审核Yondelis®用于包括脂肪肉瘤和平滑肌肉瘤亚型在内的晚期软组织肉瘤 (STS) 患者的新药上市申请 (NDA)。这些患者前期曾接受过含一种蒽环类药物的化疗。
软组织肉瘤是一种较罕见的恶性肿瘤,据美国国家癌症研究所的报道,软组织肉瘤是癌细胞形成于人体软组织的疾病,人体软组织包括肌肉、肌腱、脂肪、血管、淋巴管、神经、关节周围组织等。
软组织肉瘤几乎可形成于人体的任何部位,但最常见于头部、颈部、四肢、躯干和腹部。脂肪肉瘤和平滑肌肉瘤是软组织肉瘤的两种具体类型,前者形成于脂肪细胞,后者形成于平滑肌细胞,最常见于大腿和腹腔内。据估计,2014年美国有12000名软组织肉瘤新增病例,2015年将约有4870个人死于这一癌症。
2015年10月23日,美国食品药品监督管理局(以下简称FDA)批准化疗药Yondelis®用于治疗不可切除的或晚期(转移性)脂肪肉瘤和平滑肌肉瘤,获批的两项适应症是这种肿瘤中恶性程度较高的类型,其适应人群是既往接受过蒽环类化疗药物治疗的患者。
此次获批是基于PharmaMar公司提交的最新临床三期研究结果。在这项有518名受试者参与的研究中,经随机分配,这些受试者中有345人接受Yondelis®治疗,其余173人使用另一种化疗药dacarbazine。平均而言,Yondelis®治疗组患者的无进展生存期约为4.2个月,相比之下,dacarbazine治疗组患者只有1.5个月的无进展生存期。相比于传统化疗药物dacarbazine,Yondelis®能够显着延长患者的生存期。
FDA药品评价与研究中心的血液与肿瘤药品办公室主任Richard Pazdur博士说,“治疗晚期或转移性软组织肉瘤的难题是患者可得到的有效治疗选择少之又少,化疗药Yondelis®的获批为晚期或转移性脂肪肉瘤和平滑肌肉瘤患者提供了一种治疗选择。”

责任编辑:admin


相关文章
Emflaza Tablets/Oral Suspension(地夫可特片和口服悬液)
美国FDA批准Duchenne为首个治疗杜氏肌肉萎缩药物
Spinraza(nusinersen)注射液
美国FDA批准Spinraza为第一个治疗脊髓肌肉萎缩注射药
Rubraca(rucaparib tablets)
多发性骨髓瘤首个口服药Ninlaro获欧盟批准上市
Xiidra(Lifitegrast Ophthalmic Solution, 5%)
LARTRUVO(olaratumab injection)
Lartruvo(olaratumab)注射液联合多柔比星治疗软组织肉瘤
曲贝替定冻干粉注射剂|YONDELIS(trabectedinfor Injection)
NINLARO capsules(ixazomibitrate/MLN9708)
 

最新文章

更多

· Parsabiv(etelcalcetid...
· Litak(Cladribine solu...
· Bondronat Infusionskon...
· Bondronat Filmtablette...
· RUBRACA(rucaparib Tablets)
· ANZEMET Injection(甲磺...
· Alecensa Capsules(Alec...
· TREANDA(bendamustine h...
· LARTRUVO(olaratumab)注...
· Cabometyx(cabozantini...

推荐文章

更多

· Parsabiv(etelcalcetid...
· Litak(Cladribine solu...
· Bondronat Infusionskon...
· Bondronat Filmtablette...
· RUBRACA(rucaparib Tablets)
· ANZEMET Injection(甲磺...
· Alecensa Capsules(Alec...
· TREANDA(bendamustine h...
· LARTRUVO(olaratumab)注...
· Cabometyx(cabozantini...

热点文章

更多

· Litak(Cladribine solu...
· Parsabiv(etelcalcetid...